Comprehensive Study Guide for Neuroanesthesia and Cerebral Physiology

Anesthetic Agents and Cerebral Physiology

The majority of anesthetic agents alter intracranial pressure (ICPICP) primarily by decreasing cerebrovascular resistance (CVRCVR). This process occurs through cerebrovascular dilation and a dose-dependent impairment of cerebral autoregulation. The physiological results of these changes include increases in ICPICP and cerebral blood volume (CBVCBV) alongside a decrease in the cerebral metabolic rate of oxygen (CMRO2CMRO_2). Inhalation agents specifically decrease mean arterial pressure (MAPMAP) while increasing ICPICP, which combined reduces the cerebral perfusion pressure (CPPCPP). The relative effect of these agents on the cerebral vasculature follows the hierarchy of Isoflurane>Sevoflurane>DesfluraneIsoflurane > Sevoflurane > Desflurane.

Inhalation Agents and Neuroprotection

Isoflurane exhibits specific neuroprotective properties. Cerebral blood flow (CBFCBF) remains relatively unaltered at concentrations between 0.60.6 and 1.1 MAC1.1\,MAC. However, when the concentration is increased to 1.6 MAC1.6\,MAC, the CBFCBF doubles. Isoflurane is noted for potentially enhancing the CO2CO_2 reactivity of vessels, though cerebral autoregulation becomes impaired at doses greater than 1 MAC1\,MAC. CMRO2CMRO_2 is depressed by isoflurane, with progressive metabolic depression occurring above 1 MAC1\,MAC; the electroencephalogram (EEGEEG) becomes isoelectric at 2.5 MAC2.5\,MAC. This suggests that clinically relevant doses may protect against ischemic events.

Proposed mechanisms for this neuroprotection include the activation of ATPATP-dependent K+K^+ channels, the upregulation of nitric oxide synthase, and the reduction of excitotoxic stressors and CMRO2CMRO_2. Additionally, isoflurane may augment peri-ischemic CBFCBF and upregulate antiapoptotic factors, such as mitogen-activated protein kinases. Desflurane and Sevoflurane offer different clinical profiles. Desflurane has low blood/gas solubility, allowing for rapid emergence and immediate postoperative neurologic evaluation, though it may increase CBFCBF more than others, potentially resulting in higher ICPICP. Sevoflurane is considered less vasoactive, produces the least cerebral vasodilation, and preserves cerebral autoregulation up to 1.5 MAC1.5\,MAC.

All inhalation agents increase CBFCBF, CBVCBV, and ICPICP, though mild hyperventilation can attenuate these dose-dependent increases. They all preserve cerebrovascular CO2CO_2 reactivity and function as concentration-dependent vasodilators. In intracranial surgery, sevoflurane is often the preferred choice for maintenance anesthesia.

Nitrous Oxide and Neurosurgery Considerations

Nitrous oxide (N2ON_2O) increases CBFCBF, CMRO2CMRO_2, and ICPICP. Its effect on cerebral hemodynamics is variable; hyperventilation or the administration of intravenous anesthetics can reduce the increase in CBFCBF and CMRO2CMRO_2. When 50% N2O50\%\,N_2O is combined with less than 1 MAC1\,MAC of a volatile agent, increases in CBFCBF and CMRO2CMRO_2 occur. At 0.5 MAC0.5\,MAC, N2ON_2O can increase CBFCBF by 100%100\% or more, typically increasing flow in anterior regions while decreasing it in posterior regions.

Controversy exists regarding N2ON_2O due to potential neurotoxicity; when used for more than 12 hours12\,hours, metabolic breakdown products accumulate. It is associated with megaloblastic anemia, leukopenia, impaired fetal development, and immunosuppression. Critically, because N2ON_2O is more soluble than nitrogen, it expands closed gas spaces. It must be avoided in the presence of intracranial or intravascular air, such as pneumocephalus. If used, it should be discontinued before the closure of the dura to mitigate iatrogenic pneumocephalus formation.

Clinical suggestions for omitting N2ON_2O include cases involving recent craniotomy or craniofacial trauma, instances where evoked potential monitoring signal quality is inadequate, patients with clinical evidence of moderate to severe ICPICP increases, a clinically appreciated "tight-brain," or cases expected to last longer than 8 hours8\,hours.

Intravenous Agents and neurosurgical Considerations

Propofol is a popular agent for neurosurgery, providing dose-dependent reductions in CBFCBF and CMRO2CMRO_2 by 40−50%40-50\%. While CPPCPP may decrease due to systemic hypotension following bolus dosing, the reduction in CBFCBF appears independent of systemic changes, likely due to metabolic depression and cerebral vasoconstriction. Etomidate also reduces CMRO2CMRO_2 and CBFCBF while maintaining CPPCPP through cerebral vasoconstriction. However, its disadvantages include myoclonia, thrombophlebitis, nausea/vomiting, and adrenocortical suppression. This suppression is a concern in critically ill patients with sepsis or traumatic brain injury (TBITBI). If etomidate is used, empirical adrenal replacement therapy for 24 hours24\,hours should be considered.

Dexmedetomidine is an α2\alpha_2 receptor agonist that produces sedation without respiratory depression. It is advantageous for "wake-up" tests and brain mapping during awake craniotomies because it does not interfere with electrophysiologic monitoring, although it may cause dose-dependent decreases in motor evoked potential (MEPMEP) amplitude and Bispectral Index (BISBIS) values. It decreases CBFCBF via vasoconstriction but does not significantly alter CMRO2CMRO_2 or ICPICP. Its central sympatholytic effects assist with antishivering and reducing the neuroendocrine response to surgery.

Opioids, Benzodiazepines, and Ketamine

Synthetic opioids cause dose-related decreases in CBFCBF and CMRO2CMRO_2 (40−50%40-50\%), reducing CBFCBF to approximately 25 mL/100 g/min25\,mL/100\,g/min. While they generally offer steady hemodynamics, increases in ICPICP can occur via autoregulation if MAPMAP decreases. Sufentanil has the highest therapeutic index, while alfentanil produces the greatest decreases in MAPMAP and CPPCPP. Remifentanil has an ultrashort duration of action but carries a risk of postoperative hyperalgesia. Meperidine must be avoided due to its metabolite, normeperidine, which causes seizures. Benzodiazepines provide anxiolytic and anticonvulsant effects with dose-dependent decreases in CMRO2CMRO_2 and CBFCBF. Flumazenil reversal must be handled carefully to avoid rebound increases in CBFCBF and ICPICP or seizures.

Ketamine acts via a dissociative mechanism and was traditionally avoid in neurosurgery because it increases CBFCBF by 60−80%60-80\% and increases resistance to CSFCSF reabsorption, both elevating ICPICP. However, recent studies suggest it may not raise ICPICP as significantly as once thought. It provides stable hemodynamics and neuroprotection through noncompetitive NMDANMDA antagonism. On the EEGEEG, ketamine causes a transition from alpha to theta waves upon loss of consciousness and does not decrease BISBIS values.

Neuromuscular Blocking Agents (NMBA)

Nondepolarizing NMBAs do not affect CBFCBF or CMRO2CMRO_2. However, patients with upper motor neuron diseases may show resistance on the hemiparetic side; Train-of-Four (TOFTOF) monitoring should occur on the unaffected side. Chronic anticonvulsant therapy (PhenytoinPhenytoin) induces CYP450CYP450, leading to increased dosage requirements and decreased duration of action for these agents. Depolarizing NMBAs (succinylcholine) cause muscle fasciculations that can transiently increase ICPICP by 10−15 mmHg10-15\,mmHg for 5−8 minutes5-8\,minutes. Succinylcholine is contraindicated in patients with neurologic or denervated muscles due to the risk of hyperkalemia and should be avoided in cases of CVACVA, coma, encephalitis, or severe burns. If a rapid sequence induction (RSIRSI) is required, Rocuronium at 1.3 mg/kg1.3\,mg/kg is an alternative.

Antihypertensive Management

Beta-blockers like Esmolol (0.5−1 mg/kg0.5-1\,mg/kg) are used to control sympathetic stimulation during intubation with negligible effects on ICPICP. Labetalol is preferred for controlling emergence hypertension but is more likely to cause bradycardia. Vasodilators such as sodium nitroprusside (SNPSNP) and nitroglycerin (NTGNTG) are potent dilators of capacitance vessels and can increase CBVCBV and ICPICP. In patients with "abnormal elastance," these can lead to intracranial hypertension and potentially herniation. The effect of SNPSNP may be attenuated by hyperventilation and propofol.

Intracranial Pressure (ICP) Determinants and Monitoring

ICPICP represents supratentorial cerebrospinal fluid (CSFCSF) pressure, measured in the lateral ventricle or subarachnoid space. The Monro-Kellie Doctrine states that the cranium is a rigid container; an increase in one component—brain (80−90%80-90\%), blood, intracellular water, or CSFCSF—must be compensated for by a reduction in another, or ICPICP will rise. Intracranial contents total approximately 1200−1500 mL1200-1500\,mL. Normal ICPICP is 5−15 mmHg5-15\,mmHg, while intracranial hypertension is defined as 20−25 mmHg20-25\,mmHg. CPPCPP is calculated as CPP=MAP−ICPCPP = MAP - ICP.

The gold standard for measurement is the intraventricular catheter, which allows for both precision monitoring and continuous drainage of CSFCSF. The most frequent complication is infection (22%22\%), especially if the duration exceeds 5 days5\,days. Intraparenchymal probes are easier to transport and have a lower infection risk (1.8%1.8\%). These are recommended for severe TBITBI (GCS <9< 9) or patients with abnormal CTCT scans and specific clinical markers (age >40> 40, SBP<90 mmHgSBP < 90\,mmHg, or motor posturing).

ICP Waveforms and Intracranial Hypertension

The ICPICP waveform is pulsatile with three components: P1P_1 (arterial/systolic), P2P_2 (tidal), and P3P_3 (dicrotic). In healthy states, P1P_1 is the tallest; as ICPICP increases, P2P_2 and P3P_3 surpass P1P_1. Lundberg A waves (plateau waves) reflect sustained elevations of 40−100 mmHg40-100\,mmHg lasting 5−20 minutes5-20\,minutes, indicating critically low compliance. These are often triggered by systemic hypotension leads to cerebral vasodilation, which further increases CBVCBV and ICPICP, creating a dangerous cycle. Symptoms of intracranial hypertension include headache, nausea, papilledema, focal deficits, and decreased consciousness. If ICP>30 mmHgICP > 30\,mmHg, CBFCBF decreases, leading to ischemia and edema.

Techniques for ICP Reduction

Hyperventilation lowers PaCO2PaCO_2, causing vasoconstriction via the metabolic mechanism of autoregulation. CBFCBF decreases by approximately 4%4\% for every 1 mmH1\,mmHg decrease in PaCO2PaCO_2. This effect only lasts 11−20 hours11-20\,hours as CSFCSF pH equilibrates. Excessive hypocapnia can cause ischemia; therefore, it is not recommended in the first 24 hours24\,hours after TBITBI. The target PaCO2PaCO_2 is typically 30−35 mmHg30-35\,mmHg. External ventricular drains (EVDEVD) or ventriculoperitoneal (VPVP) shunts can divert CSFCSF to manage hydrocephalus. Surgical decompression (internal or external) is considered a last resort for uncontrollable ICPICP.

Hypothermia decreases CMRO2CMRO_2 by 7%7\% for every 1∘C1^{\circ}C decrease in core temperature. The goal is often a bladder temperature of 35−36∘C35-36^{\circ}C for 48 hours48\,hours after trauma. Pharmacologic management includes loop diuretics and osmotic diuretics like Mannitol (0.25−1 g/kg0.25-1\,g/kg). Rapid Mannitol administration can cause transient increases in CBFCBF and ICPICP due to vasodilation. Hypertonic saline (3%3\% or 23.4%23.4\%) creates an osmolar gradient that shrinks brain tissue and increases MAPMAP and CPPCPP. Serum sodium must be checked to remain below 155 mEq/L155\,mEq/L; a rise faster than 9 mEq/L9\,mEq/L in 24 hours24\,hours can cause osmotic demyelination syndrome.

Corticosteroids (Dexamethasone 4 mg4\,mg every 6 hours6\,hours) are indicated for edema related to brain tumors but are harmful in TBITBI patients (per the CRASH trial). Barbiturates may be used for refractory hypertension to induce burst suppression on the EEGEEG, though this leads to hypotension and prevents neurological examinations.

Arteriovenous Difference of Oxygen (AVDO2)

When CMRO2CMRO_2 is constant, changes in AVDO2AVDO_2 reflect changes in CBFCBF (AVDO2AVDO_2 is inversely related to CBFCBF). It is measured via a catheter in the internal jugular (IJIJ). The formula for calculation is:

AVDO2=1.34×[Hb]×SaO2−SJO2100AVDO_2 = 1.34 \times [Hb] \times \frac{SaO_2 - SJO_2}{100}

Intraoperative Neurophysiologic Monitoring (IOM)

IOM identifies brain regions at risk and improves outcomes. Common modalities include EEGEEG, somatosensory-evoked potentials (SSEPSSEP), and brainstem auditory-evoked potentials (BAEP/BAERBAEP/BAER). The Dorsal Column-Medial Lemniscal (DCMLDCML) pathway transmits sensory signals: the primary neuron enters the dorsal root and travels to the medulla, the secondary neuron crosses to the opposite side and travels to the thalamus, and the tertiary neuron reaches the somatosensory cortex. The anterolateral pathway for pain immediately synapses and crosses in the spinal cord before ascending to the thalamus.

EEGEEG waves are classified by frequency: Alpha (8−13 Hz8-13\,Hz, resting), Beta (14−80 Hz14-80\,Hz, focused), Theta (4−7 Hz4-7\,Hz, stress/disorder), and Delta (<3.5 Hz< 3.5\,Hz, deep sleep/disease). Deep anesthesia and ischemia both present with slower, larger waveforms. SSEPSSEP monitoring requires signal averaging because amplitudes are small (1−20 mV1-20\,mV). Volatile agents and N2ON_2O depress SSEPSSEP; MAC should be kept below 1 MAC1\,MAC. Conversely, etomidate and ketamine increase SSEPSSEP amplitude by 200−600%200-600\%. Hypothermia increases SSEPSSEP latency by 3 ms3\,ms for every 2−3∘C2-3^{\circ}C decrease in temperature.

BAERBAER assesses brainstem function and is resistant to most anesthetic drugs, though N2ON_2O decreases amplitude and propofol increases latency. It is helpful when the auditory apparatus is at risk. EMGEMG is used for facial nerve monitoring (standard for acoustic tumors). Neuromuscular blockers should generally be avoided when monitoring EMGEMG. Motor Evoked Potentials (MEPMEP) assess corticospinal tracts but are very sensitive to inhaled agents; Total IV Anesthesia (TIVATIVA) with propofol is the preferred anesthetic technique.

Cerebral Oximetry

Cerebral oximetry uses Near-Infrared Spectroscopy (NIRSNIRS) and the Beer-Lambert Law to measure regional venous oxygen saturation (SjO2SjO_2). It is a non-invasive monitor typically placed on the forehead. Because cerebral blood volume is roughly 75%75\% venous and 25%25\% arterial, NIRSNIRS primarily measures oxygen extraction on the venous side. A change of more than 25%25\% from baseline suggests reduced cerebral oxygenation. Factors influencing readings include BPBP, PaCO2PaCO_2, hemoglobin levels, and scalp hypoxia, which can contaminate the signal.